Antibody-drug conjugate monotherapy refines the oncological efficacy as compared to therapy of physicians’ choices in advanced breast cancers: a systematic review and meta-analysis

Background: Antibody-drug conjugate (ADC) is an emerging therapy that bestows advanced breast tumors with encouraging clinical activity and manageable toxicity; however, the outcomes of phase 2/3 randomized controlled trials (RCTs) are heterogeneous. Our study aims to assess utilities [i.e., objective response rate (ORR), benefit (CBR), progression-free survival (PFS), overall (OS)], treatment-related adverse events (AEs) ADC monotherapy (defined as cohort) versus physician’s choice (TPC) control in participants tumors.